Response to Comments: MolDX-CDD: Genomic Health™ Oncotype DX® Prostate Cancer Assay

This record (A54983) is a Response to Comments regarding draft policy DL36364 about the Genomic Health Oncotype DX Prostate Cancer Assay and does not contain the substantive coverage criteria. Because the full policy content is not provided, indications, limitations, frequency limits, and required documentation cannot be extracted from this document and require review of the complete DL36364 policy. Manual review of the underlying draft/final policy is recommended to determine coverage rules.

"This document is a 'Response to Comments' addressing comments received by Noridian Administrative Services on draft policy DL36364; the full policy text and explicit coverage criteria for the Oncot..."

Sign up to see full coverage criteria, indications, and limitations.